Apixaban and Ginkgo Biloba
Supplement–drug interaction evidence from the TruthStack database.
| Severity | HIGH |
|---|---|
| Evidence Tier | Moderate |
| Interaction Type | BLEEDING RISK |
| Mechanism | PHARMACODYNAMIC |
| Last Reviewed | 2026-02-15 |
Summary
Ginkgo has antiplatelet properties. Combining with apixaban significantly increases bleeding risk. Combination is flagged in literature or monitor closely for signs of bleeding. Discuss with your prescriber or pharmacist.
CYP Enzyme Pathway Overlap
Apixaban and Ginkgo Biloba share activity on the following CYP enzymes:
| Enzyme | Apixaban | Ginkgo Biloba |
|---|---|---|
| CYP3A4 | SUBSTRATE (MODERATE) | INDUCER (WEAK) |
Shared Pharmacodynamic Endpoints
Both compounds influence the same physiological endpoints in the same direction:
| Endpoint | Direction | Apixaban | Ginkgo Biloba |
|---|---|---|---|
| COAGULATION | DECREASE | STRONG | MODERATE |
Cumulative effect on shared endpoints may exceed individual compound profiles. This is relevant to discussion with a prescribing clinician.
API Reference
GET https://api.truthstack.co/v1/check?c1=apixaban&c2=ginkgo_biloba
Open, unauthenticated. Returns JSON. Developer documentation
Related Interactions
What this page is and is not. TruthStack is an informational reference database that describes published pharmacological findings. It does not provide medical advice, diagnosis, or treatment recommendations. The information on this page reflects flags in our database and should not replace consultation with a qualified healthcare provider. Always discuss supplement-drug combinations with your prescriber or pharmacist.